Subject(s)
Humans , Male , Female , Middle Aged , Blood Pressure/drug effects , Bisoprolol/administration & dosage , Amlodipine/administration & dosage , Drug Therapy, Combination , Irbesartan/administration & dosage , Hypertension/drug therapy , Indapamide/administration & dosage , Antihypertensive Agents/administration & dosage , Australia , Randomized Controlled Trials as Topic , Treatment OutcomeSubject(s)
Humans , Male , Adult , Shock, Cardiogenic/diagnostic imaging , COVID-19/diagnosis , Myocarditis/diagnostic imaging , Shock, Cardiogenic/drug therapy , Shock, Cardiogenic/virology , Enalapril/administration & dosage , Bisoprolol/administration & dosage , COVID-19/complications , Heart Failure/drug therapy , Heart Failure/virology , Heart Failure/diagnostic imaging , Myocarditis/drug therapy , Myocarditis/virologyABSTRACT
Two analytical methods have been developed for simultaneous quantification of bisoprolol fumarate and hydrochlorothiazide in combined pharmaceutical dosage form using spectrophotometer. Excellent simplicity, accuracy, precision and economy were achieved by the assay. The 'method I' was based upon 'simultaneous equations' whereas the 'method II' was based upon 'multicomponent mode of analysis' of the instrument. For both these methods, 0.1 N NaOH was used as solvent. In this solvent, bisoprolol fumarate showed absorbance at 224 nm and hydrochlorothiazide at 273 nm. Linearity lies in the concentration range of 3 - 21 microg/ml for bisoprolol fumarate and 3 - 18 microg/ml for hydrochlorothiazide. The methods were validated statistically and by recovery studies
Subject(s)
Hydrochlorothiazide/analysis , Spectrophotometry , Dosage Forms , Pharmaceutical Preparations , Bisoprolol/administration & dosage , Hydrochlorothiazide/administration & dosageABSTRACT
OBJETIVO: Avaliar o efeito do bisoprolol sobre a capacidade de exercício e a função ventricular em pacientes com insuficiência cardíaca. MÉTODOS: Foi feita a análise das variáveis clínicas e hemodinâmicas, da função e do remodelamento ventricular, e da ergoespirometria de pacientes com insuficiência cardíaca com diferentes etiologias, antes e após administração de bisoprolol. RESULTADOS: Foram analisados 22 pacientes, dos quais 1 paciente não tolerou a medicação e 14 pacientes alcançaram a meta do estudo. A média das idades foi de 52 anos (36 a 64 anos), 9 pacientes eram do sexo masculino e 5 eram do sexo feminino, com tempo médio de seguimento de 551 dias (238 a 1.109 dias). Foram observados melhora da classe funcional, redução da freqüência cardíaca de repouso (78,8 + 8,7 bpm vs. 63 + 6,4 bpm; p < 0,001), aumento da fração de ejeção do ventrículo esquerdo (31,3 + 8,5 por cento vs. 39 + 14,7 por cento; p = 0,043) e tendência a melhora do escore de qualidade de vida (31 + 20,6 vs. 17,8 + 14,8; p = 0,058). Ocorreu queda da freqüência cardíaca máxima no exercício (138,1 + 20,2 vs. 116,7 + 27,1; p = 0,01) e do consumo máximo de oxigênio (20,9 + 6,8 vs. 15,1 + 3,5; p < 0,001). Não houve modificação do slope VE/VCO2. Os efeitos ocorreram em todas as etiologias, inclusive na doença de Chagas. CONCLUSÃO: O bisoprolol produziu melhora clínica e hemodinâmica e de função cardíaca nas diferentes etiologias, sem, entretanto, apresentar efeitos de melhora na capacidade de exercício.
OBJECTIVE: To assess the effects of bisoprolol on exercise capacity and ventricular function in patients with heart failure. METHODS: Clinical and hemodynamic variables, ventricular function and remodeling, and ergospirometry of patients with heart failure of different etiologies were evaluated before and after the administration of bisoprolol. RESULTS: Twenty-two patients were analyzed; one patient did not tolerate medication and 14 patients reached the study goal. The group consisted of 9 men and 5 women, the mean age was 52 (36-64) years, and patients were followed during 551 days (238-1109). We observed an improvement in NYHA functional class, reduction in resting heart rate (78.8±8.7 vs 63±6.4 bpm, p <0.001), increase in left ventricular ejection fraction (31.3±8.5 percent vs 39±14.7 percent. p=0.043), and a tendency towards improved quality of life scores (31±20.6 vs 17.8±14.8. p=0.058). The maximum heart rate dropped during exercise (138.1±20.2 vs 116.7±27.1. p=0.01), as did peak oxygen consumption (20.9±6.8 vs 15.1±3.5. p<0.001); no change was observed on the EV/VCO2 slope. The effects were observed for all etiologies, including Chagas' disease. CONCLUSION: Bisoprolol was safe and well tolerated in patients with heart failure. Bisoprolol therapy improved the symptoms, hemodynamic variables, as well as the cardiac function for all etiologies; however, it did not result in improved exercise capacity.